Triple A syndrome is a rare genetic disorder caused by mutations in the achalasia-addisonianism-alacrima syndrome (AAAS ) gene which encodes a tryptophan aspartic acid (WD) repeat-containing protein named alacrima-achalasia-adrenal insufficiency neurologic disorder (ALADIN). Northern blot analysis shows that the 2.1 kb AAAS mRNA is expressed in various tissues with stronger expression in testis and pancreas. We show that human ALADIN is a protein with an apparent molecular weight of 60 kDa, and expressed in the adrenal gland, pituitary gland and pancreas. Furthermore, biochemical analysis using anti-ALADIN antibody supports the previous finding of the localization of ALADIN in the nuclear membrane. The mutations S544G and S544X show that alteration of S544 residue affects correct targeting of ALADIN to the nuclear membrane.
Introduction
Triple A syndrom e, also known as Allgrove syndrome (AS, OMIM 231550), is a rare human autosomal recessive disorder. The phenotype of the triple A syndrome features adrenocorticotropic hormone (ACTH)-resistant adrenal failure, achalasia of the cardia and alacrima (Moore et al., 1991) . In search of the gene responsible for AS, the triple A syndrome locus was linked to the chromosome 12q13 region (Weber et al., 1996) , and positional cloning efforts led to isolation of the AS-causing gene, achalasia-addisonianism-alacrima syndrome gene (AAAS) (Tallio-Pelet et al., 2000) . The AAAS gene encodes a 546-amino acid (aa) protein named alacrima-achalasia-adrenal insufficiency neurologic disorder (ALADIN), a new member of the family of tryptophan aspartic acid (WD) repeat-containing proteins.
Currently, all reported AS patients harbour mutations in the AAAS gene. Thirteen nonsense mutations, ten frameshift and five aberrant splicing mutations have been described in patients with AS (Brooks et al., 2005) . All these mutations are predicted to produce truncated proteins lacking the C-terminus, thus suggesting the importance of this region for effective ALADIN function. Five missense mutations, four in WD domains and one in the 15th aa, have also been reported. Recently, ALADIN was reported as localizing to the nuclear pore complex (NPC), and the mutants with a variety of disease-associated missense, nonsense, and frameshift mutations failed to localize to NPCs and were found predominantly in the cytoplasm. But Figure 1 . Expression of AAAS mRNA in human tissues. To determine the tissue distribution of human AAAS mRNA, the MTN blots were probed with either exon 4-16 or a part of exon 1. Q15K localized to NPCs, suggesting that this residue may be critical for the interaction of ALADIN with a protein(s) essential for the function of ALADIN but not involved in NPC localization (Cronshaw and Matunis, 2003) .
AAAS is ubiquitously expressed in all tissues tested (Tullio-Pelet et al., 2000) , but the expression of ALADIN is not reported until now.
In the present study, we determined the tissue specific expression pattern of AAAS gene in mRNA level using multiple northern blot and protein level using antibodies raised against ALADIN. These analysis may be useful in understanding of tissuespecific symptoms of AS. In addition, we further defined the minimal requirement for ALADIN targeting to the NPC using artificial mutant constructs with altered C-termini.
Results and Discussion

Cloning of a full-length AAAS cDNA
We identified a 1.4 kb insert clone, 282D10, from the normalized infant brain cDNA library (Soares et al.,1994) containing the EST 1190E. Because the mRNA transcripts for the EST 1190E were longer than 1.4 kb, the full-length cDNA was cloned by performing 5' RACE experiments using human liver total RNA as a template. The analysis of the full-length cDNA sequence revealed that it was identical to that of the AAAS gene (NM_015665).
Tissue distribution of AAAS mRNA in human
We performed Northern blot analysis to determine the tissue specificity of AAAS expression and the size of the transcript. The C-terminal probe spanning exons 4-16 recognized two transcripts, 2.1 and 2.7 kb in sizes (Figure 1 ). All tissues expressed both transcripts at various expression levels. A 85 bp DNA fragment representing a part of the first exon specifically recognized the 2.1 kb mRNA only. This exon contains the start codon of the AAAS gene, thus indicating that the 2.1 kb mRNA is the transcript encoding ALADIN. Currently, we know neither the nature of the 5' end of the 2.7 kb transcript nor the protein this transcript might encode and can not rule out the possibility that two transcripts are produced by alternative splicing in AAAS gene. The 2.1 kb mRNA was widely expressed in human tissues with strong expression in testis, pancreas, kidney and placenta ( Figure 1 ).
The relative tissue expression pattern of AAAS mRNA reported previously comprises data from tissues expressing both 2.1 and 2.7 kb transcripts, as the pattern was obtained by dot blot analysis using a probe spanning exons 7-14 (Tullio et al., 2000) . In fact, the MTN blots probed with the DNA fragment corresponding to exons 7-14 displayed a tissue expression pattern identical to that seen with the probe encompassing exons 4-6 (Supplemental Data Figure S1 and Figure 1 ). Recently, it has been reported that the splice variant of human AAAS, AAAS-v2, which contains three WD40 domains without exon 6 (Li et al., 2005) . We do not know yet whether this variant is identical to our splice variant since we did not characterize the 2.7 kb transcript. But we think that AAAS-v2 is a different transcript from 2.1 and 2.7 kb transcripts in our report because these were expressed in heart, placenta, spleen, prostate, testis, colon and The CNE19 antibody recognized a 9.6 kDa protein, while the CVL16 antibody recognized a 26 kDa protein.
(D) and (E) Western blot analysis of ALADIN in HeLa cells. FLAG-tagged ALADIN was expressed using Tet-off system as described previously (Min et al., 2003) . Upper and lower arrows indicate FLAG-ALADIN and endogenous ALADIN, respectively. peripheral blood leukocyte, while AAAS-v2 was not expressed in these tissues and had a 1.7 kb fulllength cDNA.
Expression of ALADIN in human tissues
The expression of the AAAS gene product, ALADIN, was investigated by western blot analysis using antibodies raised against two separate peptides (Figure 2A-C) . While anti-FLAG antibodies detected only fusion proteins, antibodies CNE19 and CVL16 detected an additional protein of 60 kDa from HeLa cell lysates ( Figure 2D and E), thus indicating that both antibodies were able to detect not only exogenous ALADIN but also endogenous ALADIN of molecular weight 60 kDa.
To investigate the expression of ALADIN in human tissues, western blot analysis was performed using antibody CNE19. As tissue availability was limited, we analysed ALADIN in human adrenal gland, pancreas, pituitary, kidney, skeletal muscle and placenta samples. Although several non-spe- cific signals were present, ALADIN expression was evident in pancreas, adrenal and pituitary gland ( Figure 3A) . When western blot analysis was carried out with ALADIN-adsorbed CNE19 antiserum, the ALADIN signal was specifically abolished ( Figure 3B ), while non-specific signals were unaffected. This result clearly indicated that ALADIN was expressed in the tissues mentioned.
Tissue-specific expression of ALADIN raises an interesting point with respect to ALADIN function in cells and focuses attention on tissue-specific symptoms of AS. Our results may suggest that tissuespecific expression of ALADIN in pancreas, adrenal and pituitary gland may reflect the disease-specific phenotype in AS. Interestingly, ALADIN was not detected in kidney, skeletal muscle and placenta, although AAAS mRNA expression was present. Further analysis is required to elucidate the tissuespecific symptoms of Triple A syndrome.
Subcellular localization of endogenous ALADIN
Previous studies have shown that ALADIN localizes to the NPC using GFP-tagged fusion protein. Therefore, we analysed the subcellular location of endogenous ALADIN using the CNE19 antibody. We observed that ALADIN was present mainly in the nuclear fraction ( Figure 4A ) as reported previously (Cronshaw and Matunis, 2003) . Moreover, ALADIN co-purified with the nuclear membrane when HeLa cells were fractionated into cytoplasm, nucleus, nucleoplasm and nuclear membrane ( Figure  4B ). Therefore, our data using ALADIN antibody show that endogenous ALADIN is localized in the nuclear membrane, presumably to NPC. 
Subcellular mislocalization of ALADIN mutants
The C-terminal end of ALADIN contains Ser-HisLeu (Handschug et al., 2001 ), a putative peroxisomal targeting signal 1 (PTS1) (Gould et al., 1988) . Therefore, we examined whether the SHL residues affected correct NPC targeting of ALADIN using artificial mutant constructs S544G and S544X. In contrast to the wt GFP-ALADIN which was localized to the nuclear membrane (Supplemental Data Figure S3 ), the S544G and S544X mutants were mislocalized to the cytoplasm and formed aggregates ( Figure 5A ). Cellular fractionation confirmed the cytoplasmic localization of mutants ( Figure 5B ). These results clearly indicate that the SHL is important for proper NPC targeting. There are several possible causes of mistargeting of these mutants. One possibility is the loss of NPC signal by the partial degradation of the mutant ALADIN. But it does not seem to be the case, since we can detect the same molecular weight mutant GFP-ALADINs as the wt GFP-ALADIN (Supplemental Data Figure S2 ). Another possibility is that C-terminal region around SHL is involved in ALADIN's targeting by undefined mechanisms. Those mechanisms may include binding with interacting proteins or its proper folding. Further study is needed to test this possibility. Based on the current understanding of NPC targeting signal of ALADIN, the serine residue at 544 plays a role in targeting of the nascent ALADIN.
Methods
Cloning of full-length AAAS, site-directed mutagenesis and construction of expression plasmids
The clone, 282D10, was obtained from 1NIB library (Soares et al., 1994) by screening the arrayed library filters with EST 1190E probe using Southern blot analysis. The clone contained 1.4 Kb insert and the sequence analysis revealed that it contained a partial ORF and a polyadenylation signal. To extend the cDNA, the N-terminus was amplified by 5' RACE methodology using the antisense primer 5'CTTCGCTCCTGAGAGACAGATGG3' and total liver RNA as a template. The full length cDNA of AAAS gene was subcloned at Xba I site of Flag tagged pYR31 (Min et al., 2003) . In addition, the AAAS gene was subcloned at EcoR I and Not I sites of pEGFP-C1.
To generate the mutant constructs, the site-directed mutagenesis was performed using the QuickChange mutagenesis kit (Stratagene, La Jolla, CA) according to the manufacturer's protocol. The primers for the mutant constructs were as follow: GFP-S544G; 5'TCCCCACATGGC-CACCTTCCT3', GFP-S544X; 5'ATAGTTTAGCGGCCGCT-AATGTGGGGAGTGGGGCA 3'.
Northern blot analysis
The expression level of AAAS mRNA was analyzed using human multiple tissue northern (MTN) blots according to the manufacturer's instructions (Clontech, Palo Alto, CA). The probes were prepared using Random Primed DNA Labeling Kit (Roche). The 85 bp probe for the first exon was amplified with the following primers, 5' AGATGTG -CTCTCTGGGGTTG 3' and 5' CTCTCATAGCTACTGCC-CGT 3'.
Anti-ALADIN antibodies and antibody purification
Polyclonal antibodies against human ALADIN were raised by immunization of rabbits with synthetic peptides, NELVTGSSYESPPPDFRG (CNE19, aa 23-40) and VLM -KGKPRVQDGKPV (CVL16, aa 413-427), both conjugated with keyhole lympet hemocyanin. The final antisera were affinity-purified using the peptides coupled to CNBrSepharose. Depleted CNE19 antiserum was prepared by incubating purified antiserum with bacterially expressed protein extracts containing N-terminal 33 aa of ALADIN.
Western blot analysis
Human tissues and primary cells used in experiment were obtained from St. Mary hospital of the Catholic university. The western blot analysis was performed as described elsewhere (Harlow et al., 1999) . The primary polyclonal rabbit antibodies were anti-ALADIN and anti-Lamin A (Cell Signalling Technology, Inc.). The primary mouse monoclonal antibodies were anti-FLAG (Sigma, St. Louis, MO), anti-GFP (Santa Cruz Biotechnology, Inc.), anti-EEA1 (BD Biosciences, San Jose, CA), anti-mAb414 (BAbCO, Richmond, CA) and anti-PARP (BD Biosciences, San Jose, CA). Anti-ALADIN antibodies were used in 1:3000. The detection was achieved using western blotting luminal reagent (Santa Cruz Biotechnology, Inc.).
Cell culture and subcellular fractionation of ALADIN
HeLa cells were cultured in DMEM supplemented with 10% calf serum and 50 U/ml of penicillin/streptomycin. For nuclear and cytoplasmic fractions, cells were lysed in buffer (10 mM NaCl, 1.5 mM MgCl2, 10 mM Tris-HCl (pH7.4)) for 10 min on ice. Nuclei were pelleted by centrifugation at 1,000 × g for 3 min. The pelleted nuclei were washed twice with lysis buffer. For separation of nuclear membrane, nuclear pellet was lysed in buffer (20 mM HEPES-KOH, 1.5 mM MgCl2, 420 mM KCl, 0.2 mM EDTA, 25 % glycerol). Nuclear membrane was pelleted by centrifugation at 13,000 rpm for 3 min. Cellular fractionation of mutants was performed using the NE-PER Nuclear and Cytoplasmic Extraction Reagents (Pierce) following the manufacturer's instructions.
Transfection and immunofluorescence
HeLa cells were plated in 6-well plates (2 × 10 5 cells/well) and transfected with 1 μg of plasmid DNA using 6 μl (1 mg/ml) of polyethylenimine (Sigma, St. Louis, MO). Cells grown on cover slips were fixed in 4% paraformaldehyde and permeabilized with 0.1% Triton X-100. The cells were stained with anti-mAb414 antibody (BAbCO, Richmond, CA) and secondary anti-mouse antibody conjugated to Cy3 (Jackson Laboratories) as manufacturers' recommendation. The signal was observed using Confocal microscope (Bio-Rad).
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